Condition: Metastatic Breast Cancer · Sponsor: Hoffmann-La Roche
This study will evaluate the efficacy and safety of inavolisib in combination with Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for subcutaneous use) compared with placebo in combination with Phesgo, as maintenance therapy, after induction therapy in participants with previously untreated HER2-positive advanced breast cancer (ABC).
This description comes directly from the study's public registry record.
Reference Study ID Number: WO44263 https://forpatients.roche.com/ No attachments to email below. · 888-662-6728 (U.S. Only) · global-roche-genentech-trials@gene.com
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Always discuss trial participation with your own doctor first.
| Banner Health MD Anderson AZ | Gilbert, Arizona, United States | Recruiting |
| Disney Family Cancer Center | Burbank, California, United States | Recruiting |
| City of Hope | Corona, California, United States | Recruiting |
| City of Hope Comprehensive Cancer Center | Duarte, California, United States | Recruiting |
| City of Hope at Irvine Lennar | Irvine, California, United States | Recruiting |
| Ellison Institute of Technology | Los Angeles, California, United States | Recruiting |
| Georgetown Uni Hospital | Washington D.C., District of Columbia, United States | Recruiting |
| Medstar Research Institute | Hyattsville, Maryland, United States | Recruiting |
| Dana Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| Henry Ford Hospital | Detroit, Michigan, United States | Recruiting |
| Renown Regional Medical Center | Reno, Nevada, United States | Withdrawn |
| Hackensack University Medical Center | Hackensack, New Jersey, United States | Withdrawn |
+ 180 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05894239